Head-To-Head Contrast: Oncobiologics (NASDAQ:OTLK) and Tenaya Therapeutics (NASDAQ:TNYA)

Oncobiologics (NASDAQ:OTLK) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Oncobiologics and Tenaya Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1	2	2	0	2.20
Tenaya Therapeutics	1	0	5	1	2.86

Oncobiologics presently has a consensus price target of $5.20, indicating a potential upside of 907.75%. Tenaya Therapeutics has a consensus price target of $4.00, indicating a potential upside of 923.02%. Given Tenaya Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Oncobiologics.

Profitability

This table compares Oncobiologics and Tenaya Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Institutional & Insider Ownership

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Oncobiologics and Tenaya Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35 million	93.05	-$62.42 million	($0.77)	-0.67
Tenaya Therapeutics	$1.33 million	65.67	-$90.60 million	($0.53)	-0.74

Oncobiologics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Oncobiologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500.

Summary

Tenaya Therapeutics beats Oncobiologics on 9 of the 14 factors compared between the two stocks.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.